Kite and arcellx announce expansion in strategic partnership

Santa monica, calif. & redwood city, calif.--(business wire)--kite, a gilead company (nasdaq: gild), and arcellx, inc. (nasdaq: aclx), today announced that the companies have expanded their existing collaboration, which was originally announced in december 2022. kite has exercised its option to negotiate a license for arcellx's arc-sparx program, aclx-001, in multiple myeloma, which is comprised of arc-t cells and sparx proteins that target bcma. the companies have also expanded the scope of th.
ACLX Ratings Summary
ACLX Quant Ranking